Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10–45. https://doi.org/10.3322/caac.21871

Article  PubMed  PubMed Central  Google Scholar 

Wu Y, He S, Cao M, Teng Y, Li Q, Tan N, Wang J, Zuo T, Li T, Zheng Y et al (2024) Comparative analysis of cancer statistics in China and the united States in 2024. Chin Med J (Engl) 137:3093–3100. https://doi.org/10.1097/cm9.0000000000003442

Article  PubMed  PubMed Central  Google Scholar 

Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR (2024) New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 404:803–822. https://doi.org/10.1016/s0140-6736(24)01029-8

Article  CAS  PubMed  Google Scholar 

Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H (2025) Traditional Chinese medicine in lung cancer treatment. Mol Cancer 24:57. https://doi.org/10.1186/s12943-025-02245-6

Article  PubMed  PubMed Central  Google Scholar 

Mustafa AM, El-Shiekh RA, Esmail MM, Hassan E, Senna MM, Ebid N, Elgindy AM (2025) Surveying the therapeutic potentials of Isoliquiritigenin (ISL): A comprehensive review. https://doi.org/10.1002/cbdv.202500456. Chem Biodivers e202500456

Tian T, Sun J, Wang J, Liu Y, Liu H (2018) Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells. Oncol Lett 16:6133–6139. https://doi.org/10.3892/ol.2018.9344

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Cui Y, Yao Y, Ge Y, Gan J, Jin Y, Sun G (2024) [Isoliquiritigenin modulates the effect of LINC01503 on lung squamous carcinoma Cells]. Zhongguo Fei Ai Za Zhi 27:565–578. https://doi.org/10.3779/j.issn.1009-3419.2024.102.30

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu FW, Yu CC, Hsieh PL, Liao YW, Lu MY, Chu PM (2017) Targeting oral cancer stemness and chemoresistance by isoliquiritigenin-mediated GRP78 regulation. Oncotarget 8:93912–93923. https://doi.org/10.18632/oncotarget.21338

Article  PubMed  PubMed Central  Google Scholar 

Guo S, Li Y, Su H, Meng M, Xi J, Mo G, Chen X (2021) Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. Pharm Biol 59:1260–1275. https://doi.org/10.1080/13880209.2021.1973038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu L, Chen R, Yang Q, Liu H, Zheng Q, Li L (2022) Modelling an evaluation of the efficacy and safety of gemcitabine combined with platinum in the treatment of non-small cell lung cancer. J Clin Pharm Ther 47:986–994. https://doi.org/10.1111/jcpt.13632

Article  CAS  PubMed  Google Scholar 

Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z et al (2021) Sintilimab plus platinum and gemcitabine as First-Line treatment for advanced or metastatic squamous NSCLC: results from a Randomized, Double-Blind, phase 3 trial (ORIENT-12). J Thorac Oncol 16:1501–1511. https://doi.org/10.1016/j.jtho.2021.04.011

Article  CAS  PubMed  Google Scholar 

Shi Y, Men X, Wang F, Li X, Zhang B (2024) Role of long non-coding RNAs (lncRNAs) in gastric cancer metastasis: A comprehensive review. Pathol Res Pract 262:155484. https://doi.org/10.1016/j.prp.2024.155484

Article  CAS  PubMed  Google Scholar 

Ma B, Wang S, Wu W, Shan P, Chen Y, Meng J, Xing L, Yun J, Hao L, Wang X et al (2023) Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomed Pharmacother 162:114672. https://doi.org/10.1016/j.biopha.2023.114672

Article  CAS  PubMed  Google Scholar 

Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M et al (2022) LncRNA-miRNA axis in tumor progression and therapy response: an emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother 154:113609. https://doi.org/10.1016/j.biopha.2022.113609

Article  CAS  PubMed  Google Scholar 

Xue ST, Zheng B, Cao SQ, Ding JC, Hu GS, Liu W, Chen C (2022) Long non-coding RNA LINC00680 functions as a CeRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis. Mol Cancer 21:69. https://doi.org/10.1186/s12943-022-01539-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Shao Y, Hu W, Zhang J, Shi Y, Kong X, Jiang J (2023) A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3. Cell Death Differ 30:111–124. https://doi.org/10.1038/s41418-022-01049-1

Article  CAS  PubMed  Google Scholar 

Xie M, Wang C, Sun Y, Mao Q, Sun S, Wu M, Zhu J, Li W, Jiang Z (2024) Maimendong and Qianjinweijing Tang combined with cisplatin suppressed lung cancer through targeting lncRNA-p21. J Ethnopharmacol 322:117547. https://doi.org/10.1016/j.jep.2023.117547

Article  CAS  PubMed  Google Scholar 

Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X, Wu MH (2018) Luteolin inhibits tumorigenesis and induces apoptosis of Non-Small cell lung cancer cells via regulation of MicroRNA-34a-5p. Int J Mol Sci 19. https://doi.org/10.3390/ijms19020447

Zhao Y, Shen A, Guo F, Song Y, Jing N, Ding X, Pan M, Zhang H, Wang J, Wu L et al (2020) Urinary Exosomal MiRNA-4534 as a novel diagnostic biomarker for diabetic kidney disease. Front Endocrinol (Lausanne) 11:590. https://doi.org/10.3389/fendo.2020.00590

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, Tan DSW, Veronesi G, Reck M (2024) Non-small-cell lung cancer. Nat Rev Dis Primers 10:71. https://doi.org/10.1038/s41572-024-00551-9

Article  PubMed  Google Scholar 

Zeng H, Guo A, Liu Z, Xiang S, Zheng F (2025) Isoliquiritigenin attenuates tumor progression and PD-L1 expression by inhibiting the phosphorylation of STAT3 in melanoma. Med Oncol 42:118. https://doi.org/10.1007/s12032-025-02666-9

Article  CAS  PubMed  Google Scholar 

Wang L, Li Q, Leung LK, Wong WT (2025) Licorice extract Isoliquiritigenin increased cytosol calcium and induced apoptosis in colon cancer cells via transient receptor potential Vanilloid-1. Cancer Med 14:e70705. https://doi.org/10.1002/cam4.70705

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Gu J, Pan S, Deng N, Khan M, Li L, Wu X, Li Y (2025) Synergic effect of the combination of Isoliquiritigenin and arsenic trioxide in HepG2 liver cancer cells. Cell Signal 131:111752. https://doi.org/10.1016/j.cellsig.2025.111752

Article  CAS  PubMed  Google Scholar 

Sharma D, Dhobi M, Lather V, Pandita D (2024) An insight into the therapeutic effects of Isoliquiritigenin in breast cancer. Naunyn Schmiedebergs Arch Pharmacol 397:9503–9519. https://doi.org/10.1007/s00210-024-03282-6

Article  CAS  PubMed  Google Scholar 

Zeng X, Zhao M, Yao H (2023) Anti-lung Cancer, Anti-microbial, Anti-α-glucosidase, Anti-sorbitol Dehydrogenase, and in Silico studies of Wogonoside and Isoliquiritigenin as natural compounds. J Oleo Sci 72:919–927. https://doi.org/10.5650/jos.ess23101

Article  CAS  PubMed  Google Scholar 

Ma X, Yan W, Xu P, Ma L, Zan Y, Huang L, Wang G, Liu L, Hui W (2022) LncRNA-p21 suppresses cell proliferation and induces apoptosis in gastric cancer by sponging miR-514b-3p and up-regulating ARHGEF9 expression. Biol Chem 403:945–958. https://doi.org/10.1515/hsz-2022-0153

Article  CAS  PubMed  Google Scholar 

Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, Xu W, Niu Y, Cheng L, Maity SN et al (2019) LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. Nat Commun 10:2571. https://doi.org/10.1038/s41467-019-09784-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han W, Liu J (2018) LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway. Biomed Pharmacother 97:911–918. https://doi.org/10.1016/j.biop